Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic.
The effect of topically applied retapamulin ointment was evaluated using various dosing regimens in the Staphylococcus aureus and Streptococcus pyogenes wound infection model. Retapamulin (1%, wt/wt) was efficacious using twice-daily (b.i.d.) applications for 4 or 5 days. These data underpinned the decision to evaluate 1% retapamulin b.i.d. in clinical trials.
Rittenhouse
Stephen
S
Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Rd, Collegeville, PA 19426-0989, USA. Stephen_Rittenhouse@GSK.com
Singley
Christine
C
Hoover
Jennifer
J
Page
Roni
R
Payne
David
D
D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004224:Diterpenes; D024881:Drug Resistance, Bacterial; D016106:Methicillin Resistance; D051379:Mice; D016712:Mupirocin / Q000008:administration & dosage / Q000627:therapeutic use; D009824:Ointments; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D009824:Ointments; C508887:retapamulin; D016712:Mupirocin